NPS/Enzon Merger Provides Additional Leverage In Search For Preos Partner
Executive Summary
The NPS/Enzon $1.6 bil. merger deal provides more leverage to the companies' search for a partner for the osteoporosis treatment Preos
You may also be interested in...
Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness
Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said
Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness
Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said
Dendreon/Corvas Deal Follows 2003 Merger Theme: Biotech Cash Has Caché
Dendreon is adding a second R&D campus at essentially no cost via the proposed acquisition of Corvas
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: